Sorrento Therapeutics, Inc.(SRNE.US)

Company Encyclopedia

Sorrento Therapeutics, Inc.

SRNE.US

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment.

1.931 T

SRNE.USMarket value -Rank by Market Cap -/-

Financial Score

30/01/2026 Update

BiotechnologyIndustry

Industry Ranking338/396

Industry medianC

Industry averageD

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreB
- ROE1499.52%A
- Profit Margin-852.65%E
- Gross Margin-177.70%E
Growth ScoreC
- Revenue YoY16.89%B
- Net Profit YoY-4.62%C
- Total Assets YoY-27.75%E
- Net Assets YoY-245.81%E
Cash ScoreC
- Cash Flow Margin-11.73%D
- OCF YoY16.89%B
Operating ScoreE
- Turnover0.12E
Debt ScoreE
- Gearing Ratio143.35%E

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
Swisspartners (liechtenstein) AG	0.02%	No Change	31/12/2024
Kingswood Wealth Advisors, LLC	0%	No Change	31/12/2025
The Huntington Trust Company, National Association	0%	No Change	30/09/2025
Guggenheim Partners, LLC	0%	No Change	31/08/2025
Oakworth Capital Inc.	0%	No Change	30/09/2025
Vermillion Wealth Management Inc.	0%	No Change	30/09/2025

News

Global oncology sector booming to $668B in 2034, with focus on GI tumors. 5 platforms leading the way.

A recent commentary from Oncolytics Biotech Inc. indicates that the global oncology sector is expected to grow to $668 billion by 2034, driven by a focus on gastrointestinal cancers. The report highlights the importance of research and development in oncology, suggesting a promising future for cancer treatment and the need to address GI tumors in the medical field.

Unusual Whales·Yesterday at 23:21

ONCY

-2.90%

Unusual Whales·Yesterday at 23:21

ONCY

-2.90%

Breakfast | The three major indices showed mixed results, Microsoft’s AI spending sparked concerns, and its stock price plummeted by 10%

The three major indices showed mixed results, with Microsoft's AI spending sparking concerns, causing its stock price to plummet by 10%, marking the largest single-day drop since 2020; Bitcoin fell by 6%, and Ethereum dropped over 7%, falling below $2800

Wallstreetcn·01/30/2026 07:53

The crucial role of raw material selection for success in cell therapy manufacturing

The success of cell therapy manufacturing heavily relies on the selection of raw materials, which include cell culture components, stimulants, and disposables. Quality and consistency of these materials are crucial, as variability can affect the safety and efficacy of the final product. Challenges arise when transitioning from research use only (RUO) materials to GMP-grade materials, leading to potential delays and increased costs. A risk management strategy is essential for ensuring the quality of raw materials, and collaboration with a CDMO can aid in optimizing material selection.

biopharmadive·01/30/2026 03:53

DUB inhibitors market in 7MM set to expand by 2040 due to novel therapeutics, driven by rising cancer cases.

The market for DUB inhibitors is expected to experience consistent growth due to increasing focus on targeted protein degradation and innovative oncology treatments. The rising incidence of cancer and neurodegenerative diseases also contributes to the market's expansion. The launch of new products and technologies is anticipated to propel the market further.

Unusual Whales·01/29/2026 06:33

17:31 ET DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight

The DUB inhibitors market is expected to experience significant growth by 2040, driven by the increasing prevalence of cancer and neurodegenerative diseases, along with the launch of novel therapies. Key players like InSilico Medicine and Roche are developing promising DUB inhibitors, with a focus on conditions such as Alzheimer's and Parkinson's diseases. The market is projected to expand due to broad therapeutic applications and improved diagnostics, making DUB inhibitors a vital area for future research and development in oncology and neurology.

prnewswire·01/29/2026 06:31